| NRX Stock | | | 0.70 0.04 5.41% |
Founder
Shulamit Levenberg is CoFounder Board of NurExone Biologic
| Age | 61 |
| Address | 1 First Canadian Place, Toronto, ON, Canada, M5X 1G5 |
| Web | https://nurexone.com |
NurExone Biologic Management Efficiency
The company has return on total asset
(ROA) of
(1.1431) % which means that it has lost $1.1431 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
(2.5366) %, meaning that it generated substantial loss on money invested by shareholders. NurExone Biologic's management efficiency ratios could be used to measure how well NurExone Biologic manages its routine affairs as well as how well it operates its assets and liabilities.
Total Current Assets is likely to climb to about 2
M in 2024, whereas
Total Assets are likely to drop slightly above 2.1
M in 2024.
NurExone Biologic (NRX) is traded on TSX Venture Exchange in Canada and employs 14 people. NurExone Biologic is listed under Biotechnology category by Fama And French industry classification.
Management Performance
NurExone Biologic Leadership Team
Elected by the shareholders, the NurExone Biologic's board of directors comprises two types of representatives: NurExone Biologic inside directors who are chosen from within the company, and outside directors, selected externally and held independent of NurExone. The board's role is to monitor NurExone Biologic's management team and ensure that shareholders' interests are well served. NurExone Biologic's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, NurExone Biologic's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nirit DroriCarmi, Head Development | |
| Shulamit Levenberg, CoFounder Board | |
| Daniel Offen, CoFounder Board | |
| Nirit MSc, Head Development | |
| Limor Chen, Head Partnerships | |
| Gabriel Eldor, CoFounder Manager | |
| Pr MD, Head Board | |
| Yoram Drucker, VP CoFounder | |
| Lior Shaltiel, CEO Director | |
| MBA LLM, Legal Director | |
| Ina Sarel, Quality CMC | |
| Eran MBA, Chief Officer | |
| Inbar PazBenayoun, Head Communications | |
| Meni Sofiof, Financial Controller | |
NurExone Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is NurExone Biologic a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to
measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to
predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.